Here's why Biocon share price gained 4% despite fall in profits in …

Jan 31, 2025 · Biocon share price gained 3.82 per cent at Rs 370.80 a piece on the BSE in Friday’s intraday trade after the company’s earnings for the third quarter of financial year 2024 …

CouponFollow Extension

4%
OFF

Here's Why Biocon Share Price Gained 4% Despite Fall In Profits In …

2 weeks from now

Jan 31, 2025 · Biocon share price gained 3.82 per cent at Rs 370.80 a piece on the BSE in Friday’s intraday trade after the company’s earnings for the third quarter of financial year 2024 …

business-standard.com

2%
OFF

Biocon Share Price Rises Despite Bleak Q3 Earnings

2 weeks from now

Jan 31, 2025 · Biocon Ltd. share price rose despite bleak third quarter performance. The company's consolidated net profit plunged 96.2% to Rs 25.1 crore from Rs 660 crore. ...

ndtvprofit.com

4%
OFF

Biocon Shares Up 4% Despite Sharp Fall In Profit, Find Out Why?

2 weeks from now

Jan 31, 2025 · The share price of Biocon rose almost 4% to an intra-day high of Rs 370.90 despite reporting a fall of 96.2% year-on-year in the third quarter of FY25. The company …

financialexpress.com

96%
OFF

Biocon Shares In Focus After Q3 PAT Drops 96% YoY, 1.5

2 weeks from now

Jan 31, 2025 · Biocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the company had posted a net profit of Rs …

indiatimes.com

16%
OFF

Biocon Q3 Results: Net Profit At Rs 25 Cr, Revenue At Rs 3,821 Crore

2 weeks from now

Jan 30, 2025 · Biocon Q3 FY25 results: It also reported a profit before tax (PBT) of Rs 155.9 crore, down 80.8 per cent in Q3FY25 ... Shell raises shareholder dividend despite 16% profit …

business-standard.com

4%
OFF

Biocon Shares Zoom 4% As Jefferies Upgrades To "hold" Amid …

2 weeks from now

Jan 7, 2025 · Biocon share price: This upgrade reflects a more positive outlook on the company following recent favorable news flow, particularly concerning its biologics business. ... Also …

indiatimes.com

4%
OFF

Explained: Why Biocon Share Price Climbed Over 4% In Early Trade …

2 weeks from now

Jan 13, 2025 · Biocon's share price climbed to an intraday high of Rs 377.50 per share in intraday trade on the Bombay Stock Exchange (BSE). As of 10:23 am, Biocon's stock was trading at …

indiatoday.in

96%
OFF

Biocon's Profit Struggles Continue In Q3; Net Profit Plunges 96%

2 weeks from now

Jan 31, 2025 · Biocon Q3 Profit Plunge: On a year-on-year basis, the company’s total revenue has contracted by 15 per cent to ₹3,856 crore from ₹4,519 crore. ... During the quarter, …

indiatimes.com

2%
OFF

Biocon Share Price Rises Despite Bleak Q3 Earnings - YouTube

2 weeks from now

Jan 31, 2025 · Biocon Ltd. share price rose despite bleak third quarter performance. The company's consolidated net profit plunged 96.2% to Rs 25.1 crore from Rs 660 crore....

youtube.com

50%
OFF

Biocon Q3FY24 Revenue At Rs 4,519 Cr, Up 50%; Biosimilars Up …

2 weeks from now

Feb 8, 2024 · Financial Commentary: Q3FY24 . Consolidated Revenue for Q3FY24 grew 50% year-on-year (YoY) to Rs 4,519 crore.This growth was supported by income from the divesture …

biocon.com

7%
OFF

Biocon Q3FY25 Revenue At Rs 3,856 Cr, Up 7%# EBITDA At Rs 787 …

2 weeks from now

Jan 30, 2025 · Financial Commentary: Q3FY25. Consolidated Total Revenue for Q3FY25 was at Rs 3,856 crore.Reported 7% YoY growth on a like-for-like basis, after adjusting for Branded …

biocon.com

5%
OFF

Biocon Buys Back An Investor Stake In Biologics Unit, Posts Rs 25 …

2 weeks from now

Jan 30, 2025 · Biocon's board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected to complete by February 1, …

indiatimes.com

2%
OFF

Biocon Share Price Today - Biocon Ltd Stock Price Live NSE/BSE

2 weeks from now

Biocon. Earnings and DividendsBiocon Ltd Earnings Results. Biocon Ltd’s net profit fell -96.2% since last year same period to ₹25.10Cr in the Q3 2024-2025. On a quarterly growth basis, …

indmoney.com

FAQs about Here's why Biocon share price gained 4% despite fall in profits in … Coupon?

How did Biocon share price perform in q3fy24?

Biocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the company had posted a net profit of Rs 660 crore in Q3FY24, boosted by an exceptional item of Rs 566 crore. ...

Will Biocon stock remain in focus after Q3 results?

The shares of Biocon will remain in focus on Friday after the company reported its Q3 results for FY25, posting a decline of 96% YoY in its net profit at Rs 25 crore, and also announced the acquisition of an additional 1.5% equity stake in its subsidiary Biocon Biologics. ...

What was Biocon's net profit in q3fy25?

Bengaluru-based biopharma firm Biocon on Thursday reported a consolidated net profit of Rs 25.1 crore in the third quarter of the financial year 2024-25 (Q3FY25). During the same period in the previous financial year, the company reported a loss of Rs 16 crore. ...

What is Biocon's share price?

In terms of segmental revenue contribution, Biosimilars led with 58 per cent, followed by Research Services at 24 per cent, and Generics at 18 per cent. Biocon has a total market capitalisation of Rs 43,839.91 crore. Its shares are listed at a price to earnings multiple of 1043.29 and at an earning per share of Rs 0.35, according to BSE. ...

What is Biocon Q3 results?

This functionality will provide users with ease of access navigation and enable create a new revenue line by generating leads of potential customers for brokers in a more integrated manner. Biocon Q3 results: The company reported a net loss of Rs 42 crore in the same period of the previous year ...

How did Biocon's share price rise on the BSE?

Biocon's share price climbed to an intraday high of Rs 377.50 per share in intraday trade on the Bombay Stock Exchange (BSE). As of 10:23 am, Biocon's stock was trading at Rs 376.60 per share, up 4.34% on the BSE. The VAI classification indicates that the issues identified do not warrant further regulatory action, providing relief to investors. ...